Browse
We’re here to help

Find guidance on Author Services

Login | Register

Login
Register

Cart Add to Cart

Search
Browse
We’re here to help

Find guidance on Author Services

Home
All Journals
Expert Opinion on Investigational Drugs
List of Issues
Volume 24, Issue 3

Expert Opinion on Investigational Drugs

Search in:

Advanced search Citation search

Citation search

Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site
Instructions for authors
Editorial policies
Editing services site

Journal metrics
Aims & scope
Journal information
Editorial board
News & calls for papers
Advertising information

Latest articles
Current issue
All volumes & issues
Special issues
Open access articles
Most read articles
Most cited articles

New content alerts
RSS

Subscription options & pricing

Buy a subscription

Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Register a free Taylor & Francis Online account today to boost your research and gain these benefits:

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Register now or learn more

Expert Opinion on Investigational Drugs, Volume 24, Issue 3 (2015)

Browse this journal

Latest articles
Current issue
List of issues
Special issues
Open access articles
Most read articles
Most cited articles

Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Investigational Drugs, Volume 24, Issue 3 (2015)

See all volumes and issues

Vol 33, 2024 Vol 32, 2023 Vol 31, 2022 Vol 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Volume 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994

Select to download all citations or PDFs

Download citations Download PDFs Download issue

Browse by section (All)

Display order (Default)
Published online date
Page number
Section A-Z
Most read
Most cited

Review

Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease

Nathalie Esser MD PhD, Nicolas Paquot MD PhD & André J Scheen (Professor) MD PhD

Pages: 283-307

Published online: 25 Oct 2014

AbstractforAnti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease | Full Text | References | PDF (625.6 KB)

2150 Views
179 CrossRef citations
0Altmetric

Early to Phase II drugs currently under investigation for the treatment of liver fibrosis

Peter Hauff, Ulrich Gottwald & Matthias Ocker MD

Pages: 309-327

Published online: 30 Dec 2014

AbstractforEarly to Phase II drugs currently under investigation for the treatment of liver fibrosis | Full Text | References | PDF (377.4 KB)

587 Views
23 CrossRef citations
0Altmetric

The potential role of immunotherapy to treat colorectal cancer

Manik Amin & Albert Craig Lockhart

Pages: 329-344

Published online: 17 Dec 2014

AbstractforThe potential role of immunotherapy to treat colorectal cancer | Full Text | References | PDF (624.2 KB)

1232 Views
24 CrossRef citations
0Altmetric

Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas

Alice Bergamini MD, Umberto Leone Roberti Maggiore MD, Simone Ferrero MD PhD, Emanuela Rabaiotti MD, Riccardo Viganò MD, Micaela Petrone MD, Patrizia De Marzi MD, Stefano Salvatore MD, Massimo Candiani MD & Giorgia Mangili MD

Pages: 345-362

Published online: 01 Feb 2015

AbstractforInvestigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas | Full Text | References | PDF (517.2 KB)

159 Views
1 CrossRef citations
0Altmetric

Antimalarial compounds in Phase II clinical development

Jana Held PhD, Sankarganesh Jeyaraj PhD & Andrea Kreidenweiss PhD

Pages: 363-382

Published online: 07 Jan 2015

AbstractforAntimalarial compounds in Phase II clinical development | Full Text | References | PDF (564.6 KB)

860 Views
41 CrossRef citations
0Altmetric

Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease

Peter Norman MBA PhD

Pages: 383-392

Published online: 20 Jan 2015

AbstractforInvestigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease | Full Text | References | PDF (338 KB)

1122 Views
53 CrossRef citations
0Altmetric

Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer’s disease

Douglas Walker PhD, Lih Fen Lue PhD, Gaurav Paul, Amar Patel MD & Marwan N Sabbagh MD FAAN

Pages: 393-399

Published online: 14 Jan 2015

AbstractforReceptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer’s disease | Full Text | References | PDF (191.5 KB)

540 Views
59 CrossRef citations
0Altmetric

Current Phase II investigational therapies for insomnia

Nava Zisapel PhD

Pages: 401-411

Published online: 25 Nov 2014

AbstractforCurrent Phase II investigational therapies for insomnia | Full Text | References | PDF (262.5 KB)

903 Views
24 CrossRef citations
0Altmetric

Drug Evaluation

Solabegron: a potential future addition to the β-3 adrenoceptor agonist armamentarium for the management of overactive bladder

Pamela Ellsworth (Professor of Urology) MD & Jennifer Fantasia (Medical Student) BS

Pages: 413-419

Published online: 05 Jan 2015

AbstractforSolabegron: a potential future addition to the β-3 adrenoceptor agonist armamentarium for the management of overactive bladder | Full Text | References | PDF (249.7 KB)

342 Views
5 CrossRef citations
0Altmetric

Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer

Elena Geuna MD, Andrea Milani MD, Rossella Martinello MD, Caterina Aversa MD, Giorgio Valabrega MD, Maurizio Scaltriti PhD & Filippo Montemurro MD

Pages: 421-431

Published online: 03 Feb 2015

AbstractforBuparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer | Full Text | References | PDF (407 KB)

969 Views
24 CrossRef citations
0Altmetric

Delafloxacin for the treatment of respiratory and skin infections

Matteo Bassetti, Paola Della Siega, Davide Pecori, Claudio Scarparo & Elda Righi

Pages: 433-442

Published online: 21 Jan 2015

AbstractforDelafloxacin for the treatment of respiratory and skin infections | Full Text | References | PDF (292.3 KB)

729 Views
27 CrossRef citations
0Altmetric

Explore articles

Latest
Open access
Most read
Most cited
Trending

Explore the most recently published articles

VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol

Amanda J. Hooper et al.

Editorial | Published online: 21 Jun 2024

Free Access

Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugs

Lorenza Magagnoli et al.

Review Article | Published online: 19 Jun 2024

Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development

Luca Iorio et al.

Report | Published online: 16 Jun 2024

Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study

Ling Yang et al.

Article | Published online: 3 Jun 2024

View all latest articles

Download citations

Choose format

RIS (ProCit, Reference Manager)
BibTeX
RefWorks Direct Export

Download citations

Expert Opinion on Investigational Drugs (Vol.24, Iss.3, 2015)

Access Rights

Only articles that you have access rights to view will be downloaded. The green tick (full access) and orange padlock (open access) icons indicate that you have full access.

Do you want to proceed?